Insilico doses first patient in Phase III trial of AI-designed lung disease drug
Insilico Medicine has dosed the first patient in a Phase III trial of an AI-designed lung disease drug, which is billed as a first for the industry. An analysis of rentosertib's Phase IIa trial, based on aging clocks, has been published in Nature Biotechnology.
Who is affected and how
- pharmaceuticals
- An AI-designed molecule reaching Phase III sets a benchmark for expectations on efficacy and timelines.
- doctor
- A new AI-originated active substance may join the future treatment options for lung diseases.
Sources
- Insilico Doses First Patient in Phase III Trial of an AI-Designed Lung Disease Drug — a First for the Industry — Ai Data Newsaidatanews.com · Sep 24, 2026
- China starts Phase III trial of AI drug for pulmonary fibrosisua.news · Sep 27, 2026
- [Clinical Trial Evaluation] Does Generative AI Drug Discovery Cause "Biological Rejuvenation"? Insilico Medicine Publishes Rejuvenation Trends Across 6 Aging Clocks in Phase IIa Trial of Oral TNIK Inhibitor Rentosertib in Nature Biotechnology｜JIN＠バイオDD職人note.com · Sep 22, 2026
- Generative AI in Drug Discovery: What Works in 2026dstc.org.in · Sep 24, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.